Oncologic safety of axillary lymph node dissection with immediate lymphatic reconstruction.
Axillary lymph node dissection
Immediate lymphatic reconstruction
LYMPHA
Lymphedema
Lymphovenous bypass
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
21
07
2022
accepted:
02
10
2022
pubmed:
15
10
2022
medline:
8
11
2022
entrez:
14
10
2022
Statut:
ppublish
Résumé
Immediate lymphatic reconstruction (ILR) at the time of axillary lymph node dissection (ALND) can reduce the incidence of lymphedema in patients with breast cancer. The oncologic safety of ILR is unknown and has not been reported. The purpose of this study was to evaluate if ILR is associated with increased breast cancer recurrence rates. Patients with breast cancer who underwent ALND with ILR from September 2016 to December 2020 were identified from a prospective institutional database. Patient demographics, tumor characteristics, and operative details were recorded. Follow-up included the development of local recurrence as well as distant metastasis. Oncologic outcomes were analyzed. A total of 137 patients underwent ALND with ILR. At cancer presentation, 122 patients (89%) had clinically node positive primary breast cancer, 10 patients (7.3%) had recurrent breast cancer involving the axillary lymph nodes, 3 patients (2.2%) had recurrent breast cancer involving both the breast and axillary nodes, and 2 patients (1.5%) presented with axillary disease/occult breast cancer. For surgical management, 103 patients (75.2%) underwent a mastectomy, 22 patients (16%) underwent lumpectomy and 12 patients (8.8%) had axillary surgery only. The ALND procedure, yielded a median of 15 lymph nodes pathologically identified (range 3-41). At a median follow-up of 32.9 months (range 6-63 months), 17 patients (12.4%) developed a local (n = 1) or distant recurrence (n = 16), however, no axillary recurrences were identified. Immediate lymphatic reconstruction in patients with breast cancer undergoing ALND is not associated with short term axillary recurrence and appears oncologically safe.
Identifiants
pubmed: 36239840
doi: 10.1007/s10549-022-06758-2
pii: 10.1007/s10549-022-06758-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
657-664Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
DiSipio T, Rye S, Newman B, Hayes S (2013) Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol 14(6):500–515
doi: 10.1016/S1470-2045(13)70076-7
pubmed: 23540561
Gillespie TC, Sayegh HE, Brunelle CL, Daniell KM, Taghian AG (2018) Breast cancer-related lymphedema: risk factors, precautionary measures, and treatments. Gland Surg 7(4):379–403
doi: 10.21037/gs.2017.11.04
pubmed: 30175055
pmcid: 6107585
McLaughlin SA, Wright MJ, Morris KT, Giron GL, Sampson MR, Brockway JP et al (2008) Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. J Clin Oncol 26(32):5213–5219
doi: 10.1200/JCO.2008.16.3725
pubmed: 18838709
pmcid: 2652091
Johnson AR, Fleishman A, Granoff MD, Shillue K, Houlihan MJ, Sharma R et al (2021) Evaluating the impact of immediate lymphatic reconstruction for the surgical prevention of lymphedema. Plast Reconstr Surg 147(3):373e-e381
doi: 10.1097/PRS.0000000000007636
pubmed: 33620920
Fallahian F, Tadisina KK, Xu KY (2022) Efficacy of microsurgical treatment of primary lymphedema. Ann Plast Surg 88(2):195–199
doi: 10.1097/SAP.0000000000002862
pubmed: 34398594
Chang DW, Suami H, Skoracki R (2013) A prospective analysis of 100 consecutive lymphovenous bypass cases for treatment of extremity lymphedema. Plast Reconstr Surg 132(5):1305–1314
doi: 10.1097/PRS.0b013e3182a4d626
pubmed: 24165613
Boccardo F, Casabona F, de Cian F, Friedman D, Villa G, Bogliolo S et al (2009) Lymphedema microsurgical preventive healing approach: a new technique for primary prevention of arm lymphedema after mastectomy. Ann Surg Oncol 16(3):703–708
doi: 10.1245/s10434-008-0270-y
pubmed: 19139964
Boccardo F, Casabona F, DeCian F, Friedman D, Murelli F, Puglisi M et al (2014) Lymphatic microsurgical preventing healing approach (LYMPHA) for primary surgical prevention of breast cancer-related lymphedema: over 4 years follow-up. Microsurgery 34(6):421–424
doi: 10.1002/micr.22254
pubmed: 24677148
Schwarz GS, Grobmyer SR, Djohan RS, Cakmakoglu C, Bernard SL, Radford D et al (2019) Axillary reverse mapping and lymphaticovenous bypass: lymphedema prevention through enhanced lymphatic visualization and restoration of flow. J Surg Oncol 120(2):160–7
pubmed: 31144329
Hahamoff M, Gupta N, Munoz D, Lee BT, Clevenger P, Shaw C et al (2019) A lymphedema surveillance program for breast cancer patients reveals the promise of surgical prevention. J Surg Res 244:604–611
doi: 10.1016/j.jss.2017.10.008
pubmed: 29397949
Feldman S, Bansil H, Ascherman J, Grant R, Borden B, Henderson P et al (2015) Single institution experience with lymphatic microsurgical preventive healing approach (LYMPHA) for the primary prevention of lymphedema. Ann Surg Oncol 22(10):3296–3301
doi: 10.1245/s10434-015-4721-y
pubmed: 26202566
Ozmen T, Lazaro M, Zhou Y, Vinyard A, Avisar E (2019) Evaluation of simplified lymphatic microsurgical preventing healing approach (S-LYMPHA) for the prevention of breast cancer-related clinical lymphedema after axillary lymph node dissection. Ann Surg 270(6):1156–1160
doi: 10.1097/SLA.0000000000002827
pubmed: 29794843
Coriddi M, Dayan J, Mehrara B (2020) Nomenclature in lymphedema surgery. Plast Reconstr Surg 146(3):385e-e386
doi: 10.1097/PRS.0000000000007098
pubmed: 32496381
Bedrosian I, Babiera GV, Mittendorf EA, Kuerer HM, Pantoja L, Hunt KK et al (2010) A phase I study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients. Cancer 116(11):2543–8
pubmed: 20336790
Liu S, Wang N, Gao P, Liu P, Yang H, Xie F et al (2020) Using the axillary reverse mapping technique to screen breast cancer patients with a high risk of lymphedema. World J Surg Oncol 18(1):118
doi: 10.1186/s12957-020-01886-9
pubmed: 32482174
pmcid: 7265626
Schunemann E, Dória MT, Silvestre JBCH, Gasperin P, Cavalcanti TCS, Budel VM (2014) Prospective study evaluating oncological safety of axillary reverse mapping. Ann Surg Oncol 21(7):2197–2202
doi: 10.1245/s10434-014-3626-5
pubmed: 24599413
pmcid: 4047480
Gennaro M, Listorti C, Mariani L, Maccauro M, Bianchi G, Capri G et al (2021) Oncological safety of selective axillary dissection after axillary reverse mapping in node-positive breast cancer. Eur J Surg Oncol 47(7):1606–1610
doi: 10.1016/j.ejso.2020.10.031
pubmed: 33160781
Ochoa D, Korourian S, Boneti C, Adkins L, Badgwell B, Klimberg VS (2014) Axillary reverse mapping: five-year experience. Surgery 156(5):1261–1268
doi: 10.1016/j.surg.2014.05.011
pubmed: 25444319
Abdelhamid MI, Bari AA, Farid MI, Nour H (2020) Evaluation of axillary reverse mapping (ARM) in clinically axillary node negative breast cancer patients - randomised controlled trial. Int J Surg 75:174–178
doi: 10.1016/j.ijsu.2020.01.152
pubmed: 32059974
Shaffer K, Cakmakoglu C, Schwarz GS, ElSherif A, Al-Hilli Z, Djohan R et al (2020) Lymphedema prevention surgery: improved operating efficiency over time. Ann Surg Oncol 27(12):4695–4701
doi: 10.1245/s10434-020-08890-z
pubmed: 32720042
Boneti C, Korourian S, Bland K, Cox K, Adkins LL, Henry-Tillman RS et al (2008) Axillary reverse mapping: mapping and preserving arm lymphatics may be important in preventing lymphedema during sentinel lymph node biopsy. J Am Coll Surg 206(5):1038–42 (discussion 1042-4)
doi: 10.1016/j.jamcollsurg.2007.12.022
pubmed: 18471751
Nos C, Kaufmann G, Clough KB, Collignon MA, Zerbib E, Cusumano P et al (2008) Combined axillary reverse mapping (ARM) technique for breast cancer patients requiring axillary dissection. Ann Surg Oncol 15(9):2550–2555
doi: 10.1245/s10434-008-0030-z
pubmed: 18618185
Thompson M, Korourian S, Henry-Tillman R, Adkins L, Mumford S, Westbrook KC et al (2007) Axillary reverse mapping (ARM): a new concept to identify and enhance lymphatic preservation. Ann Surg Oncol 14(6):1890–1895
doi: 10.1245/s10434-007-9412-x
pubmed: 17479341
McBride A, Allen P, Woodward W, Kim M, Kuerer HM, Drinka EK et al (2014) Locoregional recurrence risk for patients with T1,2 breast cancer with 1–3 positive lymph nodes treated with mastectomy and systemic treatment. Int J Radiat Oncol*Biol*Phys 89(2):392–8
doi: 10.1016/j.ijrobp.2014.02.013
pubmed: 24721590
Castaneda CA, Rebaza P, Castillo M, Gomez HL, de La Cruz M, Calderon G et al (2018) Critical review of axillary recurrence in early breast cancer. Crit Rev Oncol Hematol 129:146–152
doi: 10.1016/j.critrevonc.2018.06.013
pubmed: 30097233
Smidt ML, Janssen CMM, Kuster DM, Bruggink EDM, Strobbe LJA (2005) Axillary recurrence after a negative sentinel node biopsy for breast cancer: incidence and clinical significance. Ann Surg Oncol 12(1):29–33
doi: 10.1007/s10434-004-1166-0
pubmed: 15827775
van der Ploeg IMC, Nieweg OE, van Rijk MC, Valdés Olmos RA, Kroon BBR (2008) Axillary recurrence after a tumour-negative sentinel node biopsy in breast cancer patients: a systematic review and meta-analysis of the literature. Eur J Surg Oncol 34(12):1277–1284
doi: 10.1016/j.ejso.2008.01.034
pubmed: 18406100
Houvenaeghel G, Classe JM, Garbay JR, Giard S, Cohen M, Faure C et al (2016) Survival impact and predictive factors of axillary recurrence after sentinel biopsy. Eur J Cancer 58:73–82
doi: 10.1016/j.ejca.2016.01.019
pubmed: 26971077
Wangchinda P, Ithimakin S (2016) Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer. World J Surg Oncol 14(1):223
doi: 10.1186/s12957-016-0988-0
pubmed: 27557635
pmcid: 4995804
Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P et al (2017) 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. NEJM 377(19):1836–1846
doi: 10.1056/NEJMoa1701830
pubmed: 29117498
Colleoni M, Sun Z, Price KN, Karlsson P, Forbes JF, Thürlimann B et al (2016) Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the international breast cancer study group trials I to V. J Clin Oncol 34(9):927–935
doi: 10.1200/JCO.2015.62.3504
pubmed: 26786933
pmcid: 4933127
Colzani E, Johansson AL, Liljegren A, Foukakis T, Clements M, Adolfsson J et al (2014) Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, age and tumour characteristics. Br J Cancer 110(5):1378–84
doi: 10.1038/bjc.2014.5
pubmed: 24434426
pmcid: 3950882